Cochleovestibular toxicity related to dichloromethotrexate.
A 69-year-old man receiving monotherapy for lung cancer with dichloromethotrexate (DCM), and without exposure to other chemotherapeutic agents or known ototoxic drugs, developed profound cochleovestibular dysfunction. The initial presentation was vestibular. This resolved, but unilateral hearing loss ensued and continued to progress to a total of 80 db loss in the low frequency range and 40 db in the high range, despite discontinuation of the drug. Because DCM may be used in combination with the known ototoxin cisplatin, the potential of DCM as an ototoxin should also be considered in such patients.
Golden
L
L
Department of Surgery, Vincent T. Lombardi Cancer Research Center, Washington, D.C.
Ahlgren
J D
JD
Kattah
J
J
Smith
J W
JW
Sisk
R
R
Deeb
Z
Z
D000368:Aged; D015834:Cochlear Diseases / Q000139:chemically induced*; D006311:Hearing Disorders / Q000139:chemically induced*; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000009:adverse effects / Q000031:analogs & derivatives*; D015837:Vestibular Diseases / Q000139:chemically induced*
C004763:3',5'-dichloromethotrexate; D008727:Methotrexate